A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

NCT05039619 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Lupus Nephritis

Interventions

DRUG: Obinutuzumab
DRUG: Placebo
DRUG: Mycophenolate Mofetil
DRUG: Acetaminophen/paracetamol
DRUG: Diphenhydramine hydrochloride (HCl)
DRUG: Methylprednisolone
DRUG: Prednisone

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]